We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
-10.3%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$171M
AUM Growth
+$7.86M
Cap. Flow
+$22.3M
Cap. Flow %
13.05%
Top 10 Hldgs %
64.38%
Holding
54
New
21
Increased
3
Reduced
8
Closed
15

Top Buys

Rank Stock Value
1
NVS icon
Novartis
NVS
+$14.3M
2
CELG
Celgene Corp
CELG
+$13.6M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$12.2M
4
SHPG
Shire pic
SHPG
+$11.2M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$9.07M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$14.9M
2
PFE icon
Pfizer
PFE
+$10.8M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$6.02M
4
NGNE icon
Neurogene
NGNE
+$4.54M
5
LCI
Lannett Company, Inc.
LCI
+$4.44M

Sector Composition

Rank Sector Weight
1 Healthcare 82.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTK
26
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.54M 0.9%
+100,000
New +$1.3M
SGMO
27
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.53M 0.9%
+503,000
New +$1.83M
ADXS
28
DELISTED
Advaxis Inc
ADXS
$1.43M 0.84%
13,333
– –
SIOX
29
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$1.24M 0.73%
+12,500
New +$1.32M
IMDZ
30
DELISTED
Immune Design Corp.
IMDZ
$1.09M 0.64%
198,600
-106,400
-35% -$752K
CLSD
31
DELISTED
Clearside Biomedical
CLSD
$1.08M 0.63%
+8,051
New +$2.02M
RDHL
32
Redhill Biopharma
RDHL
$4.26M
$994K 0.58%
+95
New +$1.14M
GBT
33
DELISTED
Global Blood Therapeutics, Inc.
GBT
$867K 0.51%
+60,000
New +$1.05M
INDP icon
34
Indaptus Therapeutics
INDP
$272M
$791K 0.46%
+62
New +$724K
VTGN icon
35
VistaGen Therapeutics
VTGN
$9.45M
$515K 0.3%
4,604
– –
FOLD
36
CALL
DELISTED
Amicus Therapeutics
FOLD
$497K 0.29%
+100,000
New +$692K
VSTM icon
37
Verastem
VSTM
$534M
$376K 0.22%
28,000
– –
NTBL
38
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$162K 0.1%
952
– –
TCON
39
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$62K 0.04%
+64
New +$73.1K
GSK icon
40
GSK
GSK
$104B
– –
-276,000
Closed -$14.9M
NGNE icon
41
Neurogene
NGNE
$691M
– –
-17,000
Closed -$4.54M
XNTK icon
42
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.05B
– –
-400,000
Closed -$26.5M
SGEN
43
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-111,500
Closed -$6.02M
ISEE
44
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-24,000
Closed -$1.11M
SIOX
45
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-12,500
Closed -$1.32M
LCI
46
DELISTED
Lannett Company, Inc.
LCI
– –
-41,750
Closed -$4.44M
CLVS
47
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-120,000
Closed -$4.33M
AERI
48
DELISTED
Aerie Pharmaceuticals
AERI
– –
-50,000
Closed -$1.89M
TMBR
49
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
– –
-4
Closed -$32K
IMMU
50
DELISTED
Immunomedics Inc
IMMU
– –
-1,263,276
Closed -$4.11M
1
2
3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q4 2016 Portfolio in Review

As of Q4 2016, Nexthera Capital held 54 positions worth $171M, up 4.8% from $163M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Nexthera Capital deployed $22.3M of net new capital in Q4 2016, opening 21 new positions and adding to 3 existing holdings. Its largest new stake was Novartis: 220,968 shares worth $14.4M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 70% a quarter earlier.

On the sell side, the largest reduction was Pfizer, an estimated $10.8M trimmed.

  • Nexthera Capital's largest Q4 2016 buy was Novartis: 220,968 shares worth $14.4M.
  • Nexthera Capital added most to Shire pic in Q4 2016, an estimated $11.2M increase.
  • Nexthera Capital's biggest Q4 2016 reduction was Pfizer, cutting an estimated $10.8M.
  • Nexthera Capital fully exited GSK in Q4 2016, selling an estimated $14.9M.
  • Nexthera Capital's ten largest holdings make up 64% of its $171M portfolio in Q4 2016.
  • Nexthera Capital opened 21 new positions and closed 15 in Q4 2016.
  • Nexthera Capital's portfolio value rose 4.8% quarter-over-quarter to $171M.

Based on Nexthera Capital's 13F filing for Q4 2016, filed 14 Feb 2017.